علاج سرطان هامش الشرج في المرحلة II–III أو سرطان قناة الشرج في المرحلة I–III

References

DOI: 10.1016/j.annonc.2021.06.015

• Stage II-III anal margin
• Stage I-III anal canal
• Concomitant 5-FU and MMC with RT is generally recommended [I, A].
• Other options may include 5-FU and cisplatin, and in some cases, other chemotherapy (ChT) combinations can be used.
• CRT for locally advanced anal cancer should be given with an RT dose of >50 Gy; the optimal dose for different tumour stages is not known [III, B].
• The optimal RT dose for primary anal cancer is not known, but doses of at least >45-50 Gy are recommended for T1-2N0 tumours, and doses of 50.4 Gy or higher for T3-4 or N1 tumours [III, B].
• DRE has been the mainstay of determining complete response after treatment, defined as the absence of tumour and/or ulceration.
• Using data from the ACT II trial, the optimum timepoint to assess clinical tumour response after CRT was judged to be 26 weeks [II, B].